A key aim of ART-NET is to generate and disseminate national treatment protocols as a means of improving and harmonising practice. This will ultimately result in properly selected patients gaining access to and benefiting from these technologies. Such protocols will also facilitate the subsequent development of collaborative clinical trials in the UK aiming to generate a robust evidence-base on which practice change can be based.
ART-NET is underpinned by the availability of an impressive array of state-of-the-art technologies across the participating centres: all 5 centres have the technological capability to deliver SABR; ICR and the MCRC are members of the global MR-Linac Consortium and have already installed their MR-Linacs; MCRC and UCL are developing proton beam facilities, the first patient to be treated in 2018 in Manchester. A critical aspect of the network is that, even in the absence of the specific hardware, each member will make significant contributions to the physics/planning developments that will be required to translate these technologies for clinical evaluation, because the modalities do have a lot in common, in particular regarding issues related to patient geometry changes. In addition, sharing of expertise in clinical trial methodology (ICR/Leeds) and health economics (MCRC/Oxford) will add significant value to the network. ART-NET will involve a multi-disciplinary group of researchers including clinical oncologists, medical physicists, research radiographers, methodologists and health economists.
In establishing the network, each centre has signed a consortium agreement that was developed in consultation with collaborating centres and with CRUK. The agreement governs decision-making processes, management arrangements, funding, reporting and intellectual property. We have established a Steering Committee (SC) ( Table 1) for the Network, comprised of representatives from all partner institutions and a representative from CRUK.
ART-NET's mission is to:
 build a national co-operative group drawn from UK centres of excellence that will provide  co-ordinate crucial methodological developments in the design and conduct of clinical trials to streamline health technology assessments of new technologies in specific tumour types;
 lead on health economic assessments that will estimate cost savings that will be achieved through these technologies and guide the scope of investment that will be necessary across the NHS;
 conduct in silico modelling and prospective cohort studies of new technologies that will provide the rationale for subsequent response mode-funded randomised evaluations that will be disseminated across the UK;
 disseminate national treatment protocols developed through this award to other UK centres;
 train clinical researchers of the future in the field of advanced radiotherapy.
ART-NET will initially focus on a number of disease sites including prostate, rectal, lung and oesophageal cancers and central nervous system, but will subsequently establish mechanisms for ongoing research on these technology platforms in a range of other tumour types. One central, unifying theme of the network is to evaluate the new technological platforms as a means of delivering hypofractionated radiotherapy in a range of clinical indications. In recent years, the orthodox view that curative radiotherapy must be administered in conventional fractions of around 2 Gy, in order to limit normal tissue toxicities, has been overturned [8, 9] . As a result, there has been a drive towards testing hypofractionated regimens and, thus far, this has been particularly successful in lung, breast and prostate cancers [10] [11] [12] . Investigators at the ICR have led research in breast and prostate cancer that has shown that good tumour control rates can be maintained (or even improved) with equivalent levels of normal tissue damage when delivering a smaller number of larger doses of radiation. In addition to significant clinical benefits that will arise from increased use of hypofractionation, there are huge implications for the NHS, because reducing the number of treatment fractions delivered is a large cost saving. These savings will, to some extent, be offset by additional costs of delivering advanced radiotherapy. Assessment of the balance between these competing effects will be a central component of ART-NET and will provide guidance for the implementation and dissemination of the advanced treatment platforms that we are assessing.
Each platform each offer great opportunities to develop optimised hypofractionated radiation approaches, with both generic and platform-specific challenges that will need to be addressed and solved by the ART-NET investigators. Individual research workstreams ( Table 2) will be based on providing the solutions to a number of key challenges for advanced radiotherapy technologies. The strength of the ART-NET approach is that, for each of these challenges, leadership will be provided by at least 2 of the network members, with the ability to draw on expertise from each of the other centres. Importantly, the structure that we establish will be based on sharing information across the network, but it will also facilitate education and skill transfer between centres and, eventually, beyond ART-NET to the wider UK radiotherapy community.
Although the individual technologies each present their own specific challenges, we believe that there is considerable scope for lessons to be shared across the network in order to maximise research outputs and accelerate clinical translation. This collaborative framework will allow us to move away from the historical approach of single-centre early development and will significantly accelerate the process of translating each of the new technologies into the clinic. Specific . This is particularly important, given the fact that traditional phase III clinical trials may not be the most effective means of assessing some indications for these technologies.
During the 5-year funding period, we will establish an enduring UK-wide culture of collaborative working. Initially, this will be based within the 5 founding centres of ART-NET and the selected radiotherapy technology platforms. However, by the time of the completion of the Network Award, we will have engaged large sections of the UK RT community in ART-NET and will have established a framework that will drive nationwide improvements in RT. By disseminating national protocols, ART-NET will allow all centres in the UK to offer their patients state-of-the-art treatment, either in clinical trials or as standard-of-care. We anticipate that ART-NET will solve key problems relating to SABR, MR-Linac and PBT, but will also define residual problems that will need to be addressed through further funding applications beyond the period of the Network Award. We expect to be able to attract ongoing grant funding from CRUK and non-CRUK sources (e.g. MRC, NIHR) and support from industrial partners. Furthermore, the clinical research fellows in ART-NET will help to develop a skilled workforce that will be a huge asset for future radiotherapy research in the UK. Finally, the enhanced network-wide working that we will have established will ensure that future studies will be rapid and streamlined, which will benefit funders, researchers and, most importantly, patients. 
